Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 44 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Nivolumab in addition to radiation therapy for glioblastoma – first line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation	Glioma	Neurological Cancer	2018	View \| Download
Nivolumab in addition to temozolomide and radiotherapy for MGMT-methylated glioblastoma in newly diagnosed adults - first line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation , Temozolomide (Temodar; Temodal; SCH 52365)	Glioma	Neurological Cancer	2019	View \| Download
Nivolumab in combination with cabozantinib for metastatic renal cell carcinoma – first-line	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2019	View
Nivolumab in combination with chemoradiotherapy for squamous cell head and neck cancer	Cisplatin (Platinol) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Head and neck cancer	Head and Neck Cancer	2021	View \| Download
Nivolumab in combination with chemotherapy for early-stage non-small cell lung cancer – neoadjuvant	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Nivolumab in combination with chemotherapy for previously untreated unresectable or metastatic urothelial cancer	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Urothelial cancer	Urological Cancer	2022	View \| Download
Nivolumab in combination with cisplatin and fluorouracil for oesophageal cancer – first-line	5-Fluorouracil , Cisplatin (Platinol) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Oesophageal cancer	Head and Neck Cancer	2019	View \| Download
Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Bladder cancer	Oncology , Urological Cancer	2021	View \| Download
Nivolumab in combination with ipilimumab for early stage non-small cell lung cancer -neoadjuvant	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Nivolumab in combination with ipilimumab for gastric or gastroesophageal junction cancer – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Gastric cancer	Gastrointestinal Cancer	2021	View \| Download